Previous 10 | Next 10 |
Icon (NASDAQ: ICLR ): Q4 Non-GAAP EPS of $1.83 in-line; GAAP EPS of $1.76 misses by $0.07 . More news on: ICON Public Limited Company, Earnings news and commentary, Healthcare stocks news, Read more ...
Acquisition expands ICON’s global Medical Device and Diagnostic Research Services ICON plc , (NASDAQ: ICLR) a global provider of drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device industries, today announced that it h...
Highlights Net business wins in the quarter of $930 million; a book to bill of 1.28. Full year net business wins of $3.6 billion, a net book to bill of 1.30. Record closing backlog of $8.6 billion, an increase of 11.4% year on year. Quarter 4 reported revenue of $725.4 million...
Icon (NASDAQ: ICLR ) is scheduled to announce Q4 earnings results on Wednesday, February 19th, after market close. The consensus EPS Estimate is $1.83 (+13.0% Y/Y) and the consensus Revenue Estimate is $734.13M (+8.1% Y/Y). Over the last 2 years, ICLR has beaten EPS estimates 75% of ...
The following slide deck was published by ICON Public Limited Company in conjunction with this Read more ...
Highlights Full Year 2020 Revenue guidance in the range of $2,972 - $3,092 million, representing growth of 5.8 – 10.0%. Full Year 2020 Earnings per share guidance in the range of $7.55 - $7.85, representing growth of 9.7 – 14.1%. Guidance includes intention to r...
ICON plc , (NASDAQ: ICLR) a global provider of drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health organisations, today announced that Dr. Steve Cutler, CEO and Mr. Brendan Brennan, CFO of ICON plc, will...
Agilent (NYSE: A ) initiated with Overweight rating and $100 (18% upside) price target at Wells Fargo. More news on: Agilent Technologies, Inc., Avantor, Inc., Axonics Modulation Technologies, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
ICON awarded for capabilities and innovations in successful drug development and patient recruitment ICON plc, (NASDAQ: ICLR) a leading global provider of drug and medical device development and commercialisation services, has won Best Contract Research Organisation – Full-S...
ICON plc , (NASDAQ: ICLR) a global provider of drug and device development and commercialisation services to the pharmaceutical, biotechnology and medical device industries, today announced that Mr. Brendan Brennan, CFO of ICON plc, will present at Evercore ISI 2nd Annual HealthCONx Conferen...
News, Short Squeeze, Breakout and More Instantly...
ICON plc , (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been honoured in the first half of 2024 with a number of leading business and industry awards recognising the company’s leadership position in the clinical research industry, in addi...
ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today announced that it will release its financial results for the second quarter 2024 after the market closes on Wednesday, July 24, 2024. The company will hold a conference call and webcas...
ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today announced that Dr. Steve Cutler, CEO of ICON plc, will present at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 1:30pm ET. Any changes to this event and links...